News

Latest News

Stocks in Play

Dividend Stocks

Breakout Stocks

Tech Insider

Forex Daily Briefing

US Markets

Stocks To Watch

The Week Ahead

SECTOR NEWS

Commodites

Commodity News

Metals & Mining News

Crude Oil News

Crypto News

M & A News

Newswires

OTC Company News

TSX Company News

Earnings Announcements

Dividend Announcements

60 Minutes: Psychedelics Could Help People with Addiction and Anxiety

Psychedelic drug treatments are quickly going mainstream, with new coverage surfacing from 60 Minutes. In fact, they speak about how psilocybin for example is helping participants do things like quitting smoking and worrying far less. “Early results are impressive, as are the experiences of the studies' volunteers who go on a six-hour, sometimes terrifying, but often life-changing psychedelic journey deep into their own minds,” as noted by CBS News.

Helping, just days ago, the Canadian government allowed four terminally ill patients with cancer to receive psilocybin therapy to help ease end-of-life distress. This is the first time in 46 years that an exemption has been given in Canada for patients to access such treatment, says CNN. From here, such treatments could grow in popularity as research shows it can help relieve anxiety and depression in patients with advanced forms of cancer.

In addition, according to study out of NYU Langone Health, of 29 cancer patients treated with a single dose of psilocybin, about 60% to 80% showed a reduction in distress. Some of the top companies to watch as the psychedelics boom just gets under way include Revive Therapeutics (CSE:RVV)(OTC:RVVTF), Mind Medicine Inc. (OTC:MMEDF), Johnson & Johnson (NYSE:JNJ) and Numinus Wellness Inc. (TSXV:NUMI).

Revive Therapeutics Ltd. (CSE:RVV)(OTC:RVVTF) NEWSRevive Therapeutics Ltd.,  a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced back in June an expansion to the sponsored research partnership agreement entered with the University of Wisconsin-Madison to evaluate novel formulations of psilocybin and a planned Phase 1 clinical study investigating the therapeutic application of psilocybin for an undisclosed addiction use disorder.

“We are pleased to have expanded our research partnership with the University of Wisconsin-Madison in the development of novel psilocybin formulations that will serve as the platform to create unique psychedelic-based therapeutics for clinical research targeting specific medical needs, such as addiction use disorders,” said Michael Frank, Revive’s Chief Executive Officer. “As part of our psychedelic-based pharmaceutical strategy, we are focused on balancing research and development of novel psilocybin-based formulations and clinical research of psilocybin to create a robust product pipeline backed by intellectual property and clinical data with the aim to pursue the FDA regulatory pathway for commercialization. Revive plans to expand its clinical development pipeline with psilocybin for various addiction and dependence disorders.”

The research and development work being carried out at the University of Wisconsin-Madison focuses on tannin-chitosan composites in the form of thin films, hydrogels and 3D foams. The research will include the development of composite formulations, physio-chemical characterization (e.g. tensile strength of films) of composite materials and rate of psilocybin release from composites.  Final formulations will be investigated in pre-clinical and clinical studies in various diseases and disorders.  The Company has identified tannin-chitosan composite thin films as the lead candidate for the development of a unique delivery platform for therapeutic doses (1-20mg) of psilocybin into the oral cavity.

The Company also plans to finalize a sponsorship program around a Phase 1 clinical study examining psilocybin for the treatment of an undisclosed addiction use disorder.  The clinical study will be conducted at the University of Wisconsin-Madison, School of Medicine and Public Health, and School of Pharmacy, which holds a Wisconsin special authorization and DEA license to perform clinical research with psilocybin. 

Other related developments from around the markets include:

Mind Medicine Inc. (OTC:MMEDF) the leading psychedelic pharmaceutical company, has engaged renowned psychedelic assisted therapy expert Dr. Peter Gasser as an advisor to its LSD experiential therapy program Project Lucy. Dr. Gasser has pioneered the legal, medical use of psychedelics through clinical research and compassionate access in Switzerland. Dr Gasser has served as the President of the Swiss Medical Society for Psycholytic Therapy since 1997. Through compassionate access in Switzerland, Dr Gasser holds several individual treatment permissions to treat patients with MDMA and LSD. Dr. Gasser and University Hospital Basel’s Dr Matthias Liechti are conducting a Phase 2 trial of LSD assisted therapy for anxiety disorders. MindMed previously acquired the exclusive license to this ongoing Phase 2 trial through its collaboration agreement with the University Hospital Basel.

Johnson & Johnson (NYSE:JNJ) announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).  The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, in collaboration with the U.S. Department of Defense, is committing over $1 billion for this agreement. The vaccine will be provided at a global not-for-profit basis for emergency pandemic use. The U.S. government may also purchase an additional 200 million doses of Ad26.COV2.S under a subsequent agreement.

Numinus Wellness Inc. (TSXV:NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies, is pleased to announce its partnership with Together We Can Addiction Recovery and Education Society (TWC). TWC is one of Canada's largest addiction treatment organizations, a registered charity, licensed healthcare provider, and an approved Canadian Federal Government service provider for the veterans' community. The partnership has enabled TWC to enhance its mental health and addiction recovery support services with tailored mind/body wellness programs. Numinus's associated wellness clinic is benefitting from the partnership with a dedicated stream of revenue, reinitiated since the clinic's re-opening post-COVID earlier this month. The active service provider partnership is designed to ultimately support psychedelic-assisted therapies when authorized for use in Canada. One in five Canadians suffer from addiction in any given year, and deaths from the current overdose crisis attributable to opioid and other addictions are growing. Numinus and TWC share the view that new solutions and integrative approaches are needed to enhance traditional recovery-based approaches to help people make transformative change, heal, and be well. The partnership currently extends the continuum of care provided to TWC clients with specialized mind/body programs which include modalities such as naturopathy, registered massage therapy, trauma and somatic therapies, and breathwork through Numinus's associated wellness clinic in Vancouver. Individualized programs are continually being developed for TWC clients, including Canadian Forces members and veterans dealing with addiction, PTSD, anxiety, grief and loss, and other diagnoses.

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Revive Therapeutics has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of Revive Therapeutics. Please click here for full disclaimer.

Contact Information:
2818047972
[email protected]